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yses: show that the utility values of all health states are crucial determinants of the 
cost-effectiveness results. CONCLUSIONS: combined therapy resulted in greatest 
health benefits but at the same time it was the most expensive treatment option. 
Behavioral therapy was the least effective and cheapest option.
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OBJECTIVES: The buprenorphine/naloxone (BUP/NAL) combination is used in the 
treatment of prescription opioid drug dependent (OPD) patients. Previous analy-
ses demonstrated that OPD patients receiving treatment vs. no treatment, were 
associated with a reduction in the number of admissions relating to emergency 
care and psychiatric services. The objective of this study was to compare resource 
utilisation and associated healthcare costs between the OPD patients treated with 
buprenorphine/naloxone combination and OPD patients without pharmacologi-
cal treatment from the German healthcare perspective. METHODS: Two patient 
groups were selected: 1) OPD patients treated with buprenorphine/naloxone and 
2) OPD patients with no pharmacological treatment. In the absence of accessible 
large longitudinal administrative claims database in Germany, the resource use 
was estimated based on the Truven Health MarketScan Medicaid (public healthcare 
claims) database from January 01, 2007 to December 31, 2013 as a representation 
of the German population. Resource use included pharmaceutical claims, inpa-
tient care, outpatient care, and urine tests, estimated over twelve months after 
the index date. Drug costs were obtained from the German-specific source (Gelbe 
List PharmIndex) and other unit costs and length of stays using Diagnostic Related 
Group (DRG) and Einheitlicher Bewertungsmasstab (EBM). Sensitivity analyses were 
performed. RESULTS: Costs for OPD patient receiving treatment were lower in all 
categories (inpatient care, outpatient care, and urine tests), except for BUP/NAL cost. 
Total costs over 12 months were 6,033€ and 6,244€ per OPD patient with and with-
out pharmacological treatment, respectively. CONCLUSIONS: Whilst a treatment 
of prescription opioid drug dependent patients with buprenorphine/naloxone is 
associated with a medication acquisition cost, it results in public healthcare savings 
when compared to patients receiving no medication treatment.
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OBJECTIVES: Obsessive compulsive disorder (OCD) is the fourth most common mental 
disorder in the UK with a prevalence of 1.5%. UK guidelines recommend either phar-
macological or cognitive behavioural therapy (CBT) for adults with moderate func-
tional impairment. This study estimates the cost effectiveness of pharmacological, 
psychological treatments and combinations of both in the treatment of adults with 
OCD. METHODS: A decision model evaluated the cost effectiveness of selective sero-
tonin re-uptake inhibitors ( SSRIs), venlafaxine (VEN), clomipramine (CLO), behaviour 
therapy (BT), cognitive behavioural therapy (CBT), cognitive therapy (CT), fluvoxam-
ine plus cognitive behavioural therapy (FLV+CBT) and clomipramine plus behaviour 
therapy (CLO + BT). Initial consequences of therapy (0-12 weeks) were modelled using 
a decision tree. Subsequent costs and outcomes were tracked in a Markov model. 
Treatment effects (response based on YBOCS scores) and tolerability (drop outs) were 
obtained from concurrent network meta-analyses. Discounted (3.5%) health service 
costs and benefits (QALYs) over a five year period were estimated, and probabilistic 
sensitivity analyses were conducted to assess robustness of findings. RESULTS: All 
psychological and combined psycho/pharmacotherapy were more costly and had 
better outcomes than pharmacotherapies alone. CT and BT had the highest prob-
abilities (both ≈0.35) of being most cost-effective at UK thresholds. The incremental 
cost per QALY of CBT and FLV+CBT versus SSRIs were £54,280 and £129,318 respec-
tively. CONCLUSIONS: The selection of the most cost-effective therapy for adults with 
OCD is not clear-cut. The high cost-effectiveness of CT and BT is sensitive to exclusion 
of RCTs at high risk of bias. Our results are not inconsistent with UK guidance and sug-
gest that CBT is slightly more efficacious than SSRIs, but is initially more expensive. 
If an SSRI is used, the choice of drug has important economic implications. Tailoring 
the format and intensity of CBT might make it more cost-effective.
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OBJECTIVES: Schizoaffective disorder (SCA) is a complex illness with interplay of 
psychosis and mood symptoms managed with non-optimal pharmacologic regi-
mens that include antipsychotics, mood stabilizers, and antidepressants.1 The 
15-month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 
Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective 
Disorder demonstrated the benefit in delayed relapses and reduced risk of relapse 
with paliperidone palmitate once-monthly injectable (PP1M).2 This analysis esti-
mated medical costs differences among patients treated with PP1M monotherapy 
or PP1M adjunctive therapy to antidepressants or mood stabilizers versus pla-
cebo. METHODS: Rates of relapses and serious and non-serious treatment-emer-
gent adverse events (TEAEs) were derived from the trial data. Incremental annual 
medical costs for clinical events from a U.S. payer perspective were obtained from 
literatures and inflation adjusted to 2014 costs. Mean differences in total annual 
medical costs for patients treated with PP1M monotherapy and adjunctive therapy 
versus placebo were then estimated. One-way and Monte Carlo sensitivity analyses 
were additionally carried out. RESULTS: A lower rate of relapses (adjunctive therapy: 
-15.42%; monotherapy: -21.34%) and serious TEAEs (both PP1M cohorts: -3.92%) were 
associated with use of PP1M versus placebo. The average annual medical cost-offset 
per patient was -$8320.92 for monotherapy and -$6030.65 for adjunctive therapy 
driven by reduction in relapse rates and serious TEAEs. One-way sensitivity analysis 
showed that variations in relapse rates had the greatest impact on the estimated 
medical cost difference (monotherapy range: -$11,036.64, -$4,684.93; adjunctive 
therapy range: -$9,650.33, -$1,372.78). CONCLUSIONS: Use of PP1M was associated 
with significantly lower relapse rates and consequently a substantial reduction in 
medical costs. Patients treated with PP1M monotherapy resulted in even a greater 
medical cost saving. Further evaluation to assess the impact of monotherapy option 
in real-world setting is warranted.
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OBJECTIVES: Reductions in prices following the expiry of patents on second-
generation antipsychotics means that they could be made available to patients 
with Schizophrenia in low-income countries. In this study we examine the cost-
effectiveness of of 5 antipsychotics—chlorpromazine, haloperidol, risperidone, 
olanzapine and quetiapine—for the treatment of Schizophrenia in Uganda to 
inform national-level policy and clinical decision making. METHODS: We devel-
oped a decision-analytic 3-state (outpatient, inpatient, and dead) Markov model 
to represent the clinical course of Schizophrenia and the experience of the aver-
age patient with the Uganda healthcare system. The model was run for a base 
population of 18-year-old patients attending Butabika National Referral Mental 
Hospital, in 3-monthly cycles over a lifetime horizon. Parameters were derived 
from a primary chart abstraction study, a local community pharmacy survey, 
published literature and expert opinion where necessary. We computed mean 
DALYs and costs (in $US) for each antipsychotic, incremental cost and DALYs 
averted as well as Incremental Cost Effectiveness Ratios (ICER). RESULTS: In the 
base-case analysis, mean DALYs were highest with chlorpromazine (30.17), fol-
lowed by haloperidol (29.48), while olanzapine (28.90) and risperidone had the 
lowest DALYs (28.99). Expected costs were highest with quetiapine ($6,777), and 
lowest with haloperidol ($6,404). Compared to chlorpromazine, haloperidol was 
a dominant strategy (i.e., it was less costly and more effective). ICERs comparing 
risperidone to haloperidol and olanzapine to risperidone were $372 and $1400 
per DALY averted. CONCLUSIONS: Policy makers and clinicians should consider 
haloperidol as the first line agent for Schizophrenia in Uganda. Further, at com-
monly accepted thresholds (between 1 and 3 times the Gross Domestic Product 
of Uganda), risperidone is highly cost-effective and olanzapine is cost-effective, 
therefore policymakers should consider adding these agents to essential medi-
cines lists for treatment of Schizophrenia.
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OBJECTIVES: The primary objective was to estimate incremental cost-effectiveness 
of vortioxetine, a serotonin modulator and simulator (SMS) versus desvenlafaxine, 
a serotonin-norepinephrine reuptake inhibitor (SNRI), as potential first line medi-
cations for treatment of mild or moderate major depression. The clinical benefit 
of a SMS may be in faster onset and shorter time to remission. Evidence suggests 
vortioxetine causes fewer adverse drug events (ADEs) than desvenlafaxine, which 
has implications for discontinuation of therapy. METHODS: A decision tree was 
constructed to model the cost effectiveness of these two agents from the societal 
perspective. Parameters were obtained from published clinical trial data, a meta-
analysis using indirect treatment comparison, observational studies, preference 
elicitation studies, and cost estimates from Average Wholesale Prices for medica-
tions and claims analyses for cost of medical care. The model assumed that patients 
achieved remission. The time horizon was 48 weeks and included opportunities 
to switch medication therapy at 8 weeks and relapse at 24 weeks. Incremental 
cost-effectiveness ratios (ICERs) were calculated using the number of discontinu-
ations averted, relapses averted, and quality adjusted life years (QALYs) gained as 
outcomes. One-way sensitivity analyses were conducted. RESULTS: The ICER was 
$77,800 per QALY gained, $59,500 per relapse averted, and $58,500 per averted dis-
continuation due to ADEs. The parameter that was least robust was a utility value 
of maintenance therapy for vortioxetine or desvenlafaxine applied to weeks 8-48 
(0.80, range: 0.78-0.82; 0.76, range 0.74-0.78, respectively). Time to remission was 
varied from 6-10 weeks. A shorter time to remission for vortioxetine provided mod-
est improvements in the ICER while a longer time to remission increased cost over 
the point estimate of $77,800 per QALY gained ($69,000-$88,900 per QALY gained, 
respectively). CONCLUSIONS: Model results suggest that there is value in invest-
ing in vortioxetine over desvenlafaxine. A potentially faster time to remission for 
vortioxetine would result in increased value.
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OBJECTIVES: Major depressive disorder (MDD) is an important public health prob-
lem in South Korea, with a lifetime prevalence of 6.7%. Current antidepressants do 
not fully meet needs in depression, so additional options are required. We assessed 
the cost-utility of vortioxetine (a new antidepressant with multimodal activity) ver-
susvenlafaxine XR in MDD patients in South Korea initiating these antidepressants 
or switching to them due to inadequate response to previous treatment. METHODS: 
A one-year cost-utility analysis from a societal perspective was performed using 
an initial decision-tree model, which included suicide risk, followed by a Markov 
model (2-month cycles) for subsequent treatments. Remission, relapse and recovery 
were the main health states. In first line, efficacy at two months was derived from 
the Asian SOLUTION study (vortioxetine vs. venlafaxine XR; NCT01571453) and for 
switching patients from REVIVE (vortioxetine vs. agomelatine; NCT01488071) and 
STAR*D (pragmatic trial of several antidepressants). STAR*D was the efficacy source 
for subsequent lines of treatment. Adverse event probabilities were included to 
consider the impact on quality of life and costs. Utilities were derived from REVIVE 
and adverse event disutilities from the literature. Resource use and productivity 
estimates were obtained from a survey of 28 Korean physicians. Korean 2013/2014 
costs were applied. Deterministic and probabilistic sensitivity analyses were con-
ducted. RESULTS: Vortioxetine dominated venlafaxine XR, with QALY gains of 
0.0155 and a cost difference of KRW 576,433 [US$532] (KRW 3,334 [US$3] when pro-
ductivity not considered) over one year. The model showed a greater proportion 
of patients in recovery after initial treatment with vortioxetine (31.4%) compared 
with venlafaxine XR (23.4%). These results were confirmed to be robust through 
sensitivity analysis; vortioxetine remained dominant in 97% of probabilistic simula-
tions. CONCLUSIONS: Vortioxetine dominated venlafaxine XR in South Korea and 
therefore appears to be a relevant treatment option for MDD patients initiating or 
switching therapy.
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OBJECTIVES: To evaluate the cost-effectiveness of bipolar disorder (I and II) treat-
ments to assist in efficient resource allocation. METHODS: A population based 
model was developed to estimate the cost per disability adjusted life year (DALY) 
averted for efficacious therapies to treat adults with bipolar disorder. The model is 
based on the 2013 Australian population with the Global Burden of Disease (GBD) 
prevalence estimates applied. All-cause mortality attributable to bipolar disorder 
is incorporated as well as the decreased rate of suicide attributable to lithium. 
Disability weights from GBD are used to calculate DALYs. The evaluation takes a 
health sector perspective and used standard costs for medications and other medi-
cal services obtained from Australian sources. All treatments with proven efficacy 
were sourced from current systematic reviews/meta-analyses and supplemented 
with expert clinical input. Treatments evaluated included monotherapy with atypi-
cal antipsychotics, anticonvulsants, and lithium as well as combination therapies 
evaluated in randomized controlled trials. Psychological therapies were evaluated 
as adjunctive to medications. Electroconvulsive therapy was evaluated as a treat-
ment in the depressive phase only. RESULTS: Preliminary results suggest that 
among monotherapies, valproate produced the lowest cost per/DALY $AUD 53,000/
DALY (CI $35,000 - $84,000). Oxcarbazepine plus lithium provided the lowest cost 
among combinations $104,000/DALY (CI dominant - $446,000). Adding a disorder 
specific psychotherapy was less cost effective than pharmacotherapy alone for 
lower cost treatments (lithium, valproate) and more cost effective for aripiprazole, 
olanzapine, quetiapine, and combinations. Adherence costs will be varied in future 
analysis and presented. CONCLUSIONS: Preliminary results indicate treatments 
generally exceeded the commonly accepted $AUD 50,000/DALY threshold for cost-
effectiveness. From an economic perspective, valproate would be recommended 
as initial therapy. Higher cost therapies, including most combinations, should be 
implemented with a psychological intervention.
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OBJECTIVES: Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed 
antidepressants. This claims database study compared healthcare resource use and 
costs among patients with major depressive disorder (MDD) treated with vilazodone, 
versus other SSRIs. METHODS: Adults with an MDD diagnosis and ≥ 1 prescription 
fill for vilazodone, citalopram, escitalopram, fluoxetine, paroxetine or sertraline 
were identified from the Truven Health MarketScan® Research Databases (January 
1, 2010 to December 31, 2012). Patients who concomitantly used adjunctive medica-
tion, either a second-generation antidepressant or antipsychotic, were excluded. 
All-cause and MDD-related healthcare resource use and costs (measured from a 
payer’s perspective in 2012 US dollars) over a 6 month period post-index date were 
compared among treatment groups using multivariate robust Poisson regression 
and robust linear regression, respectively, adjusted for age, gender, insurance type, 
index year, comorbidities, prior antidepressant treatment, and pharmacy copay-
ment at baseline (12 months pre-index date). RESULTS: The study cohort included 
49,861 patients (mean age: 44.0 years; 70% female). Compared with the vilazodone 
cohort (N= 3,527), patients in the citalopram (N= 12,187), escitalopram (N= 8,275), 
fluoxetine (N= 10,142), paroxetine (N= 3,146), and sertraline (N= 12,584) cohorts had 
significantly more all-cause inpatient (IP) visits, length of IP stay and emergency 
room (ER) visits, and MDD-related IP visits and length of IP stay following the index 
date, after adjusting for baseline characteristics. All-cause medical service costs (IP + 
outpatient + ER) were significantly higher across all other SSRI cohorts versus vilazo-
done by $758 to $1,165 (P< 0.05). Similarly, all-cause total costs were also significantly 
or numerically higher across all SSRI cohorts versus vilazodone by $351 to $780 after 
accounting for prescription costs. CONCLUSIONS: MDD treatment with vilazodone 
was associated with significantly lower rates of inpatient and emergency services, 
and with significantly lower all-cause medical service and numerically lower total 
costs to payers compared to other SSRIs included in this study.
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OBJECTIVES: Describe estimated health resource (HR) and criminal justice (CJ) sys-
tem costs by treatment failure status for young patients with schizophrenia that 
participated in the Paliperidone palmitate Research In Demonstrating Effectiveness 
(PRIDE) clinical trial involving recently incarcerated subjects. METHODS: HR and 
CJ events were collected via a resource use questionnaire and were combined 
with cost estimates obtained from administrative claims and published literature 
to estimate costs at 15 months (trial duration). Treatment failure was defined in 
the clinical trial as having any of the following: an arrest/incarceration, psychi-
atric hospitalization, suicide, discontinuation of antipsychotic treatment due to 
inadequate efficacy, treatment supplementation with another antipsychotic due 
to inadequate efficacy, discontinuation of antipsychotic treatment due to safety 
or tolerability, or increase in the level of psychiatric services in order to prevent 
imminent psychiatric hospitalization. Costs, in 2011 US dollars, were estimated by 
failure status (Yes/No) for young subjects (defined as those ≤ 35 years of age) and 
summarized descriptively using a state government payer perspective. RESULTS: 
Estimated cost per person for young subjects with a failure (n= 104) were $45,590 
versus $24,586 for young subjects without a failure (n= 57). Cost differences were 
greater for the failure group relative to no failure group for criminal justice system 
events ($20,961) acute care events ($4,722) and outpatient care ($524). Within the 
failure group, extrapolating out to the 15 month trial duration, criminal justice 
system events were a common cause of failure in this analysis with an estimated 
86.5% expected to have a criminal justice system contact and 70.2% expected to 
be incarcerated. CONCLUSIONS: From a state government perspective, provision 
of early interventions that reduce treatment failure among young patients may 
avoid substantial cost.
Mental HealtH – Patient-reported outcomes & Patient Preference studies
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OBJECTIVES: Life satisfaction is affected by social, economic, disease and health-
related living conditions. Depressive disorders are known to be an important burden 
for life satisfaction, whereas social support from family or peer groups can substan-
tially buffer this impact. The objective of this contribution is to analyse the comple-
mentary influences of depression and social support on life satisfaction. METHODS: 
In 2012, two representative population samples of the non-institutionalized adult 
population in Germany and UK were surveyed (n= 4,008) and self-reports about 
satisfaction with life as a whole, health, social life, functioning, income and social 
life were collected. Five years earlier, in 2007, the same individuals had reported on 
chronic diseases, health care, health status and social and living conditions, as well 
as depression diagnosis and treatment. Multiple linear regression allows to estimate 
the prospective five-year impact of depression, multimorbidity (score of 22 chronic 
diseases) and social support on life satisfaction. RESULTS: In 2007, 13.3% of the 
German and 21.3% of the UK sample had suffered from depression. In 2012, 65.0% of 
the individuals in UK and 73.9% in Germany reported to be “satisfied” or “very satis-
fied” with “life as a whole”. In the group of individuals with “no depression” in 2007, 
75.2% of the individuals reported positive life satisfaction in 2012. Among individu-
als with medically diagnosed depression in 2007, the fraction was 42.3%. Multiple 
linear regression resulted in a strong positive buffering effect of social support 
(beta= .225; p< .00) on life satisfaction and a substantial negative impact of depres-
sion (beta= -.167; p< .00) in 2012. Age had very small effect (beta= .076;p< .00) and the 
influence of gender was not statistically significant. CONCLUSIONS: Depression 
has a negative impact on life satisfaction, which can partly compensated by good 
social support.
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OBJECTIVES: To elicit caregivers’ preferences for evidence-based treatment options 
for their child’s attention deficit hyperactivity disorder (ADHD), and to identify seg-
ments of caregivers who display similar preferences. METHODS: Caregivers with 
a child aged 4–14 and in care for ADHD were recruited from outpatient clinics and 
advocacy groups. All caregivers completed a self-administered survey that included 
socio-demographic information, and a best-worst scaling (BWS) instrument assess-
ing treatment preferences. The BWS instrument comprised 18 choice tasks, each 
